Corporate Sponsors

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. 

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

AstraZeneca

Our approach

Even as research and development continues to break boundaries in how we understand and fight cancer, there are still more than eight million lives lost every year to the disease.

At AstraZeneca, we are committed to advancing the science of oncology to deliver life-changing medicines to patients most in need. With a combination-focused pipeline that exploits the power of four scientific platforms to help address unmet clinical needs in a host of cancers, we are motivated by a dedication to the scientific discovery and collaboration that will one day help eliminate cancer as a cause of death.

CHOC

CHOC was established to function as a group purchasing organization for POHMS members and to share any benefits derived from group purchasing activities.

CHOC selects a preferred vendor, based on a competitive bid process, to provide aggressive drug pricing, payment terms and a variety of related services eligible to CHOC member practices.  CHOC's current preferred vendor is McKesson Specialty Health. 

CHOC believes every practice has full control over their ability to buy whatever drugs they choose. CHOC’s goal is to assist members with making well-informed decisions at the best available price.

CHOC's vision is to provide an optimal drug-purchasing environment for Hematology Oncology practices.

Daiichi-Sankyo, Inc.

Incyte Corporation

Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. 

Since 2002 Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders.  

Incyte’s unique expertise in medicinal chemistry and biology have enabled us to create a diversified pipeline of clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing portfolio of medicines across two franchises: Oncology and Inflammation & Autoimmunity. 

Headquartered in Wilmington, Delaware, Incyte has operations in the U.S., Europe and Japan.  

For more information, visit Incyte.com and follow @Incyte. 

McKesson

McKesson empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we improve the financial health of our community oncology practice customers and help them provide quality care for patients.

AbbVie Inc

About AbbVie in Oncology
At AbbVie, we strive to discover and develop medicines that deliver transformational improvements in cancer treatment by uniquely combining our deep knowledge in core areas of biology with cutting-edge technologies, and by working together with our partners – scientists, clinical experts, industry peers, advocates, and patients. We remain focused on delivering these transformative advances in treatment across some of the most debilitating and widespread cancers. We are also committed to exploring solutions to help patients obtain access to our cancer medicines. With the acquisitions of Pharmacyclics in 2015 and Stemcentrx in 2016, our research and development efforts, and through collaborations, AbbVie's oncology portfolio now consists of marketed medicines and a pipeline containing multiple new molecules being evaluated worldwide in more than 200 clinical trials and more than 20 different tumor types. For more information, please visit http://www.abbvie.com/oncology.

Array Biopharma Inc

Array Today
Array markets in the United States BRAFTOVI^™ (encorafenib) capsules in combination with MEKTOVI^®(binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF^V600E or BRAF^V600K mutation as detected by an FDA-approved test.* Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant colorectal cancer. 

Values 
At Array, we embrace three core values that guide our day-to-day activities:

1. Integrity and transparency in what we do and how we do it
2. A sense of urgency and creativity in bringing benefit to patients
3. The knowledge to achieve our critical objectives

Lilly

Lilly is a pioneer in chemotherapy drugs, having introduced vincristine and vinblastine in the 1960s. These anticancer drugs, known as vinca alkaloids, were derived from the rosy periwinkle plant. In 1996, Lilly leveraged this expertise with the introduction of GEMZAR® (gemcitabine HCl for injection) for the treatment of non-small cell lung cancer, pancreatic cancer, and metastatic breast cancer.

Novartis

Alexion

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). As the leader in complement biology for over 20 years, Alexion focuses its research efforts on novel molecules and targets in the complement cascade, and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. 

Oncology Supply

Oncology Supply is the nation’s largest distributor of Chemotherapy drugs & Supplies, earning a respected name in the wholesale specialty arena with more than 30 years of experience.  For the community-based oncology practice, Oncology Supply has become the first choice for reliability, stability, integrity and honesty.   Bringing technology to the forefront, Oncology Supply’s Nucleus® cabinet offers support and solutions for your practice’s inventory management needs.  Our goal is to deliver responsive and innovative solutions to help our business partners positively impact cancer patients’ lives. For more information, visit www.oncologysupply.com.

Taiho Oncology Inc

Alexion Pharmaceuticals

AMAG Pharmaceuticals

Biologics Inc.

Boehringer Ingelheim Oncology

Coherus BIOSCIENCES

Eagle Pharmaceuticals

Eusa Pharma

Exelixis

GenPath

Guardant Health

Inform Diagnostics

Ipsen

Kyowa Kirin

Mylan Inc.

Onco 360, Oncology Pharmacy

Pfizer

Spectrum Pharmaceuticals

Syenos

Teva Oncology

Unlimited Systems